SEC Filings
Eton Pays $10.0 Million Upfront For U.S. Rights To Aquestive's Libervant, With Up To $47.5 Million More In Milestones
The license adds a mid-teens royalty and a 20-year supply deal, and Eton anticipates an April 2027 launch, subject to final FDA approval.